c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression
HGF/c-MET upregulation is frequent in bladder cancer. Here, the authors show that HGF induces EMT and invasion by stabilising TGFβ receptor through inhibition of the SMURF2 ligase, and the combined blockade of MAPK and TGFβ pathways suppresses HGF-mediated bladder cancer progression.
Guardado en:
Autores principales: | Wen Jing Sim, Prasanna Vasudevan Iyengar, Dilraj Lama, Sarah Kit Leng Lui, Hsien Chun Ng, Lior Haviv-Shapira, Eytan Domany, Dennis Kappei, Tuan Zea Tan, Azad Saei, Patrick William Jaynes, Chandra Shekhar Verma, Alan Prem Kumar, Mathieu Rouanne, Hong Koo Ha, Camelia Radulescu, Peter ten Dijke, Pieter Johan Adam Eichhorn, Jean Paul Thiery |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c563b6db7c52440f8cb6c74048d684b4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression
por: Wen Jing Sim, et al.
Publicado: (2019) -
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Lun-Xi Peng, et al.
Publicado: (2021) -
Targeting MET in cancer therapy
por: Hong-Nan Mo, et al.
Publicado: (2017) -
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
por: Li Ren Kong, et al.
Publicado: (2020) -
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)